OncoMatch/Clinical Trials/NCT07086456
Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung Cancer
Is NCT07086456 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Surufatinib and Tislelizumab for surufatinib.
Treatment: Surufatinib · Tislelizumab · Concurrent Chemotherapy — This is a prospective, single-arm, phase II clinical study designed to evaluate the efficacy and safety of surufatinib and tislelizumab in combination with concurrent chemoradiotherapy, followed by consolidation therapy with tislelizumab plus surufatinib, in patients with unresectable, locally advanced stage III non-small cell lung cancer (NSCLC).
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR driver gene mutation
Presence of EGFR or ALK driver gene mutations [excluded]
Required: ALK driver gene mutation
Presence of EGFR or ALK driver gene mutations [excluded]
Disease stage
Required: Stage IIIA, IIIB, IIIC
Performance status
WHO 0–1
Lab requirements
Blood counts
Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L; Platelet count ≥ 100 × 10⁹/L; Hemoglobin ≥ 9.0 g/dL
Kidney function
Serum creatinine clearance ≥ 50 mL/min (Cockcroft-Gault formula)
Liver function
Total serum bilirubin ≤ 1.5 × upper limit of normal (ULN); AST and ALT ≤ 2.5 × ULN
Adequate organ and bone marrow function as defined by the following criteria: Forced expiratory volume in 1 second (FEV1) ≥ 800 mL; Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L; Platelet count ≥ 100 × 10⁹/L; Hemoglobin ≥ 9.0 g/dL; Serum creatinine clearance ≥ 50 mL/min (Cockcroft-Gault formula); Total serum bilirubin ≤ 1.5 × ULN; AST and ALT ≤ 2.5 × ULN. Average QTc ≥ 470 ms excluded.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify